^
Association details:
| Biomarker: | PTEN-L |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | ipatasertib (RG7440) (PI3K inhibitor, AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors (LOTUS)
Excerpt:
PFS in Participants With Phosphatase and Tensin Homolog (PTEN)-Low Tumors...
Trial ID:
Source:
Title:
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
Published date:
07/15/2021
Excerpt:
...median OS favored ipatasertib-paclitaxel in the PTEN-low (n = 48; 23.1 vs 15.8 months; hazard ratio 0.83)
Secondary therapy:
paclitaxel
DOI:
10.1007/s10549-021-06143-5
Trial ID:
Source:
Title:
139O - Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
Published date:
05/23/2020
Excerpt:
In the ITT population, median OS was numerically longer in the IPAT + PAC arm (Table). Similarly, median OS favoured IPAT + PAC vs PBO + PAC in the PTEN-low (n=48; 23.1 vs 15.8 mo) and PIK3CA/AKT1/PTEN-altered (n=42; 25.8 vs 22.1 mo) subgroups.
Secondary therapy:
paclitaxel
Trial ID:
